Headache News

Mindfulness-based stress reduction appeared to safely treat total migraine burden with long-lasting effects, according to findings presented at the annual meeting of the American Neurological Association.

The American Academy of Neurology released a position statement that highlights the significant challenges high drug prices create for patients, physicians, health systems and payers.

The cause of midlife migraines in women is likely multifactorial, though research suggests that fluctuating hormone levels may play a role, according to a speaker at the North American Menopause Society annual meeting.

The FDA has approved Qulipta for the prevention of migraine.

Individuals with migraine had much poorer subjective sleep quality and altered sleep architecture vs. healthy individuals, according to results of a meta-analysis published in Neurology.

Longer duration of perimenstrual migraine attacks among women with menstrual-related migraine appeared linked to increased recurrence risk and triptan use, according to results of a prospective study published in Neurology.

The FDA approved dihydroergotamine mesylate for the treatment of adults with acute migraine with or without aura, according to a press release from the drug’s manufacturer.

Oral atogepant once per day effectively decreased the number of migraine and headache days over 12 weeks, according to findings from the phase 3 ADVANCE trial that were published in The New England Journal of Medicine.

Migraine correlated with “abnormal modulation” of visual motion stimuli in different areas of the brain that further related to migraine disability and motion sickness susceptibility, according to findings published in Neurology.

Occipital nerve stimulation significantly reduced attack frequency and was safe and well-tolerated in patients with medically intractable chronic cluster headaches, according to a study published in Lancet Neurology.